Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
Date:4/29/2008

>About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or c
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
2. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
3. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
4. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... China, Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, ... active pharmaceutical ingredients (API) released unaudited preliminary financial ... 2015. Fiscal Year 2015 Ended September ... $9.7 million compared with $14.7 million in 1Q14 ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... 25, 2011 Omthera Pharmaceuticals, Inc., a privately-held emerging ... has joined the Company as Vice President of Quality. ... Operating Officer, Drs. Ben Machielse, Mr. Maines will be ...   Mr. Maines brings to the Company ...
... 2011 GlaxoSmithKline, one of the world,s leading ... 10 winners of its GlaxoSmithKline IMPACT Awards. In ... organizations will receive $400,000 in grant funding for ... their communities. Three of the North ...
Cached Medicine Technology:Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality 2GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards 2GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards 3
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based ... practice and med-spa with the addition of new Silk ... cosmetic treatments and services. , “Silk Peel is a ... Dr. Ho. “As a result it can address issues ... spots, discolorations or blemishes.” , Similar to microdermabrasion, ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 Today, Yunx.co.uk, ... of evening dresses and other special occasion outfits, ... new models are offered at discounted prices, up to ... the young ladies with their fashionable designs, gorgeous looks ... no exception. The business is devoted to designing and ...
(Date:12/24/2014)... BambooIndustry.com a famous bamboo flooring company offering ... company announces its multiple layer bamboo panel board ... new products. , Bamboo panel is the product made ... bamboo panel board features high quality selective bamboo and ... The bamboo panel consists of multiple layers of bamboo. ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Hepatitis C infection ... according to a new study. Treatment advances have made ... but many develop memory and thinking problems, mood swings and ... authors said. It,s believed that long-term infections with other ... may affect the brain. One of the prime suspects has ...
(Date:12/24/2014)... (HealthDay News) -- Researchers say they have used human ... eggs and sperm. While this had already been ... time that these types of cells -- called primordial ... stem cells, according to the team at the University ... germ cells is one of the earliest events during ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2
... EAGAN, Minn., Feb. 9 Blue Cross and Blue Shield of Minnesota ... manager of the largest database of vendored disease management programs. The awards ... reducing adverse health events for its members. Blue Cross, disease management efforts ... diabetes , ...
... Equips Participants with Tools to Live Healthy, Active LivesCLEVELAND, ... Clinic has consistently sought to shift the national focus ... part of this commitment , Cleveland Clinic has ... helps reverse and decrease the effects of several common ...
... boosts well-being, study suggests, , , MONDAY, Feb. 9 (HealthDay ... buy happiness, purchasing life experiences instead of material possessions ... a study that asked more than 150 older college ... them happy, researchers found that people were more satisfied ...
... the Top Achievements in 50 Years of Women,s Health RARITAN, ... globulin product, celebrates its 40th year in the marketplace helping ... Newborn (HDN). In 1968, a new mother at Holy ... initial recipient of the world,s first injectable treatment to prevent ...
... intended to prevent HIV infection in women has demonstrated ... in Africa and the United States. Findings of the ... Allergy and Infectious Diseases (NIAID), part of the NIH, ... Opportunistic Infections in Montreal. , The study investigators ...
... Cancer Research Center have discovered a mechanism in liver metabolism ... in severe metabolic disorders. Mice suffering from metabolic syndrome or ... called LSR in the liver, as reported by researchers headed ... As a result, only small amounts of fat are ...
Cached Medicine News:Health News:Blue Cross Receives Disease Management Awards 2Health News:Blue Cross Receives Disease Management Awards 3Health News:Cleveland Clinic Launches Ground-Breaking Wellness Program To Reverse Effects of Common Chronic Diseases 2Health News:Cleveland Clinic Launches Ground-Breaking Wellness Program To Reverse Effects of Common Chronic Diseases 3Health News:Cleveland Clinic Launches Ground-Breaking Wellness Program To Reverse Effects of Common Chronic Diseases 4Health News:Experiences Bring More Joy Than Possessions Do 2Health News:Experiences Bring More Joy Than Possessions Do 3Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 2Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 3Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 4Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 5Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 6Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 7Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 8Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 9Health News:Anti-HIV gel shows promise in large-scale study in women 2Health News:Anti-HIV gel shows promise in large-scale study in women 3Health News:Anti-HIV gel shows promise in large-scale study in women 4Health News:Pathologically elevated blood fat levels in obesity: Researchers discover molecular causes 2
Medium clip size, 10mm...
... in 10mm and 5mm sizes. Our market-leading ... placement., ,The LIGACLIP ERCA Endoscopic Rotating ... patient use instrument designed to provide a ... The instrument delivers 20 titanium clips that ...
... utilizes turbidimetric immunoassay methodology which is a ... of 0.2-28.0 mg/dL. This assay is homogeneous, ... clinical chemistry analyzers. The Wako CRP-HS assay ... linearity, correlation, and sensitivity. Expected values are ...
... Piccolo is the first compact, broad menu ... testing in any treatment setting. Care givers ... panels with less than one minute of ... comparable in quality to larger, expensive laboratory ...
Medicine Products: